Photo from wikipedia
Glucagon‐like peptide‐1 (GLP‐1) and glucagon (GCG) receptor dual agonist have promising therapeutic effects in the treatment of obesity and diabetes. Moreover, GLP‐1 and cholecystokinin 2 (CCK2) dual agonists have been… Click to show full abstract
Glucagon‐like peptide‐1 (GLP‐1) and glucagon (GCG) receptor dual agonist have promising therapeutic effects in the treatment of obesity and diabetes. Moreover, GLP‐1 and cholecystokinin 2 (CCK2) dual agonists have been shown to restore pancreas function and improve glycaemic control in preclinical studies. We describe, for the first time, the beneficial effects of GLP‐1/glucagon receptor and GLP‐1/CCK2 dual agonists, which can be integrated into one peptide, resulting in significant anti‐diabetes and anti‐obesity effectiveness.
Journal Title: British Journal of Pharmacology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!